Skip to main content
Equibles

PHAR · Pharming Group N.V. · Earnings Call Transcripts & Audio

Track PHAR — free

Use PHAR with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research PHAR.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$11.00 -0.21 (-1.87%)
Rebalance outlook locked
Market Cap
$793.42M
Shares
70.78M

Pharming Group N.V. Earnings Call Transcripts

Quarterly earnings calls for Pharming Group N.V. (PHAR), with available speaker-labelled transcripts, captured audio replays, call highlights, 8-K earnings releases and periodic filings. Investor days and conferences appear here too.

Pull transcripts and briefs through the earnings call transcript API or MCP →
Conference
Investor event
2026-09-14
Pharming Group N.V. (PHAR) September 2026 Conference
Scheduled
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q2
2026-07-30
Pharming Group N.V. (PHAR) Q2 2026 Earnings Call Transcript
Positive tone Ruconest resilience vs oral on-demand competitor Joenja/leniolisib commercial growth Geographic expansion and ex-U.S. launch readiness
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q1
2026-05-07
Pharming Group N.V. (PHAR) Q1 2026 Earnings Call Transcript
Positive tone Joenja commercial growth and patient expansion RUCONEST revenue decline and inventory dynamics Pipeline programs in PIDs, CVID and mitochondrial disease
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q3
2025-09-30
Pharming Group N.V. (PHAR) Q3 2025 Earnings Call Transcript
Confident tone Joenja/APDS franchise expansion RUCONEST commercial growth RUCONEST ex-U.S. withdrawal
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-06-30
Pharming Group N.V. (PHAR) Q2 2025 Earnings Call Transcript
Confident tone Joenja (leniolisib) commercialization in APDS RUCONEST growth and market position APDS patient pool expansion via VUS reclassification
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-03-31
Pharming Group N.V. (PHAR) Q1 2025 Earnings Call Transcript
Confident tone Joenja (leniolisib) commercial uptake and catalysts RUCONEST revenue growth and commercial performance G&A cost reduction initiative
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2024-12-31
Pharming Group N.V. (PHAR) Q4 2024 Earnings Call Transcript
Confident tone Joenja (leniolisib) launch and APDS franchise RUCONEST revenue growth and HAE market position Pipeline expansion into larger indications (APLS, CVID)
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-09-30
Pharming Group N.V. (PHAR) Q3 2024 Earnings Call Transcript
Positive tone Joenja/leniolisib launch and growth RUCONEST commercial performance Financial performance and guidance
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-06-30
Pharming Group N.V. (PHAR) Q2 2024 Earnings Call Transcript
Confident tone Joenja launch momentum RUCONEST performance and growth Pipeline expansion / leniolisib indications
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-03-31
Pharming Group N.V. (PHAR) Q1 2024 Earnings Call Transcript
Confident tone Joenja/leniolisib launch in APDS Revenue guidance and quarterly dynamics RUCONEST franchise performance
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2023-12-31
Pharming Group N.V. (PHAR) Q4 2023 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-09-30
Pharming Group N.V. (PHAR) Q3 2023 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-06-30
Pharming Group N.V. (PHAR) Q2 2023 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-03-31
Pharming Group N.V. (PHAR) Q1 2023 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2022-12-31
Pharming Group N.V. (PHAR) Q4 2022 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-09-30
Pharming Group N.V. (PHAR) Q3 2022 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-03-31
Pharming Group N.V. (PHAR) Q1 2022 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q3
2021-09-30
Pharming Group N.V. (PHAR) Q3 2021 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-06-30
Pharming Group N.V. (PHAR) Q2 2021 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-Q
Showing 1–19 of 19 earnings calls
Key facts CIK 1828316 CUSIP 71716E105 13F (30d) 4 filings 3 filers Visit website Investor relations